Latest Health News

Xero Limited has reported a robust FY25 with 23% revenue growth and a Rule of 40 score exceeding 44%, underscoring its balanced approach to growth and profitability.

NEXION Group has entered a non-binding agreement to sell its Perth data centre subsidiary to Canadian firm Carrier Connect Data Solutions for AUD 2.5 million, aiming to strengthen its balance sheet.

Mayne Pharma has voluntarily withdrawn a speaker presentation for its contraceptive NEXTSTELLIS® following an FDA Untitled Letter concerning promotional claims. The company confirms this does not impact sales or its planned merger with Cosette.

Health and Plant Protein Group Ltd (HPP) has received a US$3.38 million tax refund from the US IRS linked to its 2023 US subsidiary sale, slightly exceeding prior estimates. The company plans to return surplus assets to shareholders and pursue strategic growth opportunities under a leaner cost structure.

Smartgroup Corporation Limited reported robust financial growth in 2024, driven by record customer numbers and a significant rise in electric vehicle leasing, positioning the company for a sustainable future.

Microba Life Sciences reveals preliminary data from over 4,600 MetaXplore GI Plus tests showing significant clinical findings in the majority of patients, with two-thirds reporting symptom improvements following test-guided care.

Lumos Diagnostics has secured its largest single US purchase order for its rapid respiratory test FebriDx, signaling growing adoption in American healthcare settings.

Raptis Group Limited has voluntarily suspended trading on the ASX as it prepares to announce a significant share placement and entitlement offer, signaling a pivotal moment for the company’s capital structure.

Universal Biosensors reports solid growth in its wine testing segment and outlines plans for a capital raise alongside the upcoming AQUASCOUT water testing device launch.

Universal Biosensors reported a 6% increase in revenue for Q1 2025 but posted a net loss of A$3.84 million, with cash reserves sufficient only through Q3 2025, raising questions about its financial sustainability.

Bio-Gene Technology Limited has launched a Share Purchase Plan allowing Australian shareholders to invest up to $15,000 at 2.3 cents per share, matching a recent $2.1 million placement. The offer includes free-attaching options, subject to shareholder approval, to support key product development milestones.

Envirosuite Limited has entered a binding Scheme Implementation Deed with UK-based Ideagen Limited, agreeing to a full acquisition at a significant premium. The transaction values Envirosuite at approximately A$132.2 million and awaits shareholder and regulatory approvals.